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BACKGROUND: Cellular senescence is a terminal cell-cycle arrest that occurs in response to activated oncogenes and DNA-damaging
chemotherapy. Whether cancer cell senescence at diagnosis might be predictive for treatment outcome is unknown.
METHODS: A senescence index (SI) was developed and used to retrospectively correlate the treatment outcome of 30 UICC stage IV
colorectal cancer (CRC) patients with their SI at diagnosis.
RESULTS: 5-Fluorouracil/leucovorin-treated CRC patients achieved a significantly longer progression-free survival when presenting with
SI-positive tumours before therapy (median 12.0 vs 6.0 months; P¼0.044).
CONCLUSION: Cancer cell senescence predicts treatment outcome in metastasised CRC. Prospective analyses of larger patient cohorts
are needed.
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In the past, many cancer studies sought to link quantitative
assessments of tumour growth properties, namely proliferation
and apoptosis, to treatment outcome, but the majority of these
analyses produced negative results for various reasons. Although
relevant as a prognosticator, the value of using the mitotic index to
predict treatment outcome is very limited (see Schmitt, 2003, 2007;
Brown and Attardi, 2005; Yerushalmi et al, 2010 and references
therein for review). A third cancer-related growth condition is
oncogene-induced senescence (OIS), a terminal cell-cycle arrest
initiated by activated Ras-type oncogenes that functions as a
tumour-suppressive barrier in pre-malignant lesions in vivo (Braig
et al, 2005; Michaloglou et al, 2005; Collado and Serrano, 2010;
Reimann et al, 2010). Oncogene-induced senescence is mediated
through an oncogene-evoked DNA damage response (DDR)
(Bartkova et al, 2005, 2006; Gorgoulis et al, 2005), thereby
explaining why DNA-damaging chemotherapy produces senes-
cence as well (Chang et al, 1999; Schmitt et al, 2002). Therapy-
induced senescence (TIS) contributes to treatment outcome in
pre-clinical models (Schmitt et al, 2002), and is detectable in
patient cancer biopsies after neoadjuvant chemotherapy (te Poele
et al, 2002; Roberson et al, 2005), but its long-term effect on
clinical courses remains undetermined. We hypothesised that
senescent cells present sporadically in untreated cancers at
diagnosis may indicate an increased susceptibility to TIS, and,
thus, might be associated with a superior clinical outcome. Because
the gold-standard senescence assay, detection of the senescence-
associated b-galactosidase (SA-b-gal) activity (Dimri et al, 1995),
cannot be applied to formalin-fixed and paraffin-embedded
(FFPE) clinical routine samples, we developed a senescence index
(SI) based on FFPE-suitable immunohistochemical surrogate
markers. We report here the first-time use of this SI in untreated
human tumour specimens at diagnosis as a predictor for outcome
to cancer therapy.
MATERIALS AND METHODS
Patients and tumour material
Snap-frozen or FFPE samples of normal colon mucosa, colon
adenoma and colon carcinoma were collected, and informed
patient consent was obtained for the anonymous use of the
material. FFPE tumour samples from previously untreated 30
patients with UICC stage IV colorectal cancer (CRC) all of whom
received a 5-fluorouracil/leucovorin (5-FU/LV)-based first-line
regimen were subjected to senescence evaluation, reflecting the
available archive material in our pathology department between
the years 1996 and 2002 that met these criteria. Tissue material
from patients suspected or diagnosed with a hereditary cancer
syndrome or inflammatory bowel disease, or whose chemotherapy
was terminated for reasons other than disease progression was
excluded from this study. Clinical data sets were compiled in a
retrospective and anonymous manner, and included gender, age,
tumour location, carcinoembryonic antigen (CEA) serum levels,
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sTNM classification, tumour grading and progression-free survival
(PFS), defined as the time from first diagnosis until diagnosis of
progressive disease (i.e. local recurrence of the primary lesion, or
growth of metastases or occurrence of new metastatic lesions).
Retroviral infection
IMR90 human fibroblasts (CCl-186 from American Type Culture
Collection, Manassas, VA, USA) were stably transduced with the
pBabe-Puro-H-RasV12 retrovirus (provided by S Lowe) or an
empty vector as a control, and selected in puromycin as described
(Serrano et al, 1997; Braig et al, 2005). Cell pellets were snap frozen
in liquid nitrogen or processed as FFPE pellets comparable to
patient tissue samples.
Immunohistochemical analysis
Cryosections (12mm) were acetone fixed and exposed to an anti-
Ki67 primary antibody (M7240, 1:250 dilution; Dako, Glostrup,
Denmark) for 30min. Antibody binding was visualised by a
chromogenic substrate in a streptavidin/alkaline phosphatase-
amplified secondary antibody according to the manufacturer’s
recommendations (K0689, K0698, K0625, X3021, all from Dako).
FFPE sections (7mm) were subjected to heat-induced antigen
retrieval before incubation with primary antibodies for 30min.
Primary antibodies against Ki67 (as above), heterochromatin
protein 1g (HP1g; MAB3450, 1:250 dilution; Chemicon/Millipore,
Billerica, MA, USA), phospho-activated ERK1/2 (p-ERK, no. 4376,
1:50 dilution; Cell Signaling Technology, Danvers, MA, USA),
plasminogen activator inhibitor-1 (PAI-1 (i.e. Ncl-PAI-1), 1:20
dilution; Novocastra, Newcastle upon Tyne, UK) or cleaved
caspase-3/Asp175 (no. 9661, 1:200 dilution; Cell Signaling
Technology) were used, followed by the appropriate secondary
antibody along with a streptavidin/alkaline phosphatase conjugate
or streptavidin/peroxidase kit and suitable chromogenic substrates
such as 3,30-diaminobenzidine or Fast Red (K0690, K3468, K5005,
all from Dako).
The formula and the cut-off values of the SI were generated
based on the expression (i.e. the percentage of positive cells by
immunostaining) of the three markers p-ERK, HP1g and PAI-1 in
low-proliferating areas (arbitrarily defined as o12 Ki67-positive in
an area of 100 cells) in a learning set of five adenoma samples. For
each of the three markers, a factor was generated that reflects the
reciprocal percentage of cells that stained positive in such areas
averaged over these five adenomas. This factor was used as a
coefficient to equalise the marker’s relative individual contribution
to the SI. Moreover, a linear correction value was added to set the
discrimination threshold to 0. Values between  1 and þ1 were
considered ‘non-conclusive’. Senescence index values of individual
cancer samples were obtained in low-proliferating areas as well
(see Figure 2 for further information on SI-related technical
procedures).
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Figure 1 Stratification of stage IV CRC samples by a senescence index (SI) predicts PFS to first-line 5-FU/LV therapy. (A) Proportions of senescent cases
in cryo-preserved colorectal tissue sections of the indicated groups (normal crypt mucosa (n¼5, 0 senescent); adenoma (n¼12, 8 senescent), invasive
carcinoma (n¼6, 1 senescent)). Note that 9 out of 12 adenoma and 2 out of 6 carcinoma cases would score ‘senescent’ if judged in low-proliferating areas
only (see D). (B) Average frequency of senescent cells per group (as in A), measured as the percentage of SA-b-gal-positive (blue) cells, and compared to
the rate of Ki67-positive (red nuclear staining) cells (top: error bars represent the standard deviation; bottom: matched areas of representative
photomicrographs – a non-senescent normal crypt mucosa, a senescent adenoma and a formally non-senescent carcinoma (but showing numerous
senescent cells)). Notably, in normal colorectal mucosa, only cells of the most differentiated luminal mucosa stain SA-b-gal-positive. (C) FFPE sections of
pelleted Ras-infected senescent (sen.) human fibroblasts (SA-b-gal-positive and Ki67-negative frozen material as a reference) show much stronger
immunoreactivity for p-ERK, HP1g and cytoplasmic PAI-1 when compared with non-senescent (non-sen.) mock-infected fibroblasts. (D) SI values, based on
the expression of these three markers, were obtained in 30 cases of stage IV CRC specimens at diagnosis, and used to stratify PFS following 5-FU/LV first-line
chemotherapy (senescent (n¼12; blue line) vs non-senescent (n¼17; red line); one case scored ‘not conclusive’ (see Figure 2B)). Genomic sequencing in a
subset of these 29 specimens identified K-Ras codon 12 or 13 mutations in 5 out of 6 senescent, but only 2 out of 11 non-senescent cases (inset). Note that
a primary stratification by the K-Ras mutation status unveiled no significant differences in PFS (P¼0.128).
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Senescence-associated b-galactosidase activity was detected at
pH 6.0 in cryo-preserved cells or tissue sections as described
(Dimri et al, 1995; Braig et al, 2005). Cases were considered
senescent if their mean percentage of SA-b-gal-positive cells was
higher than the mean percentage of Ki67-positive cells.
Ras mutation analysis
Genomic DNA was extracted from macro-dissected tumour areas
of FFPE tissue sections using the QIAamp DNA Mini kit (Qiagen,
Hilden, Germany). PCR amplification of the first exon of the k-ras
gene was performed according to van den Brandt and colleagues
(Brink et al, 2003). The resulting 179bp PCR product was
sequenced using the BigDye Terminator v1.1 Cycle Sequencing
kit on a 3130 Genetic Analyzer (Applied Biosystems, Foster City,
CA, USA). Hotspot codon 12 or 13 mutations were detected by
comparison with the germ-line sequence.
Statistical analysis
Statistical analyses (SPSS software package, release 17.0; SPSS,
Munich, Germany) of Kaplan–Meier survival plots were based on
the log-rank (Mantel–Cox) test; additional statistical comparisons
used the Wilcoxon–Mann–Whitney test (to probe equal distribu-
tion of age, frequency of Ki67-reactive and cleaved caspase-3-
positive cells, and serum CEA levels in patient subgroups), the
Fisher’s exact test (with respect to gender, tumour localisation,
sites of distant metastasis (one vs more than one) and Ras
mutations) and the w
2-test (regarding the pT and the pN status).
P-values o0.05 were considered statistically significant.
RESULTS
We analysed 23 snap-frozen colorectal tissue samples of normal
mucosa, adenomas and untreated invasive carcinomas by the SA-b-
gal assay, complemented by immunostaining for the proliferation
marker Ki67 and confirmed the reportedly high frequency of
senescent cells in adenomas, leading to the classification of 8 out of
12 adenoma cases tested as senescent, which is well in line with
their macroscopic presentation as polyps of often stable size for
years (Figure 1A and B; see the flow diagram in Figure 2A for
technical details) (Bartkova et al, 2006). Importantly, as previously
reported for a subset of lymphoma, lung and breast cancer
specimens at manifestation (te Poele et al, 2002; Roberson et al,
2005; Reimann et al, 2010), we detected a significant fraction of
senescent cells within neoplastic epithelial areas of manifest
colorectal carcinomas, possibly indicating a still available senes-
cence programme at this full-blown cancer stage (Figure 1A and B).
Because the enzymatic SA-b-gal assay cannot be applied to FFPE
routine samples, or substituted by a single marker, we tested
protein expression levels of a panel of DDR mediators, cell-cycle
regulators, chromatin-related proteins and others (Bartkova et al,
2006; Collado and Serrano, 2006) in a well-established OIS
reference model system – sections of either snap-frozen or FFPE
pellets of Ras-senescent vs proliferating fibroblasts – that allowed
us to compare SA-b-gal staining and potential immunohistochem-
ical surrogate markers in the same material side by side (Serrano
et al, 1997). Using this fibroblast model system followed by first a
learning and then a validation set of adenoma samples, we
generated a senescence surrogate score (SI) based on the
expression of p-ERK, HP1g and PAI-1 – all of them previously
linked to OIS (Serrano et al, 1997; Lin et al, 1998; Narita et al,
2003) – that recapitulated SA-b-gal reactivity and adenoma
senescence (Figure 1C; Figure 2).
Senescence index (SI)
Flow diagram
SI > +1: senescent
SI < –1: non-senescent
–1  SI  +1: not conclusive
17 validation set adenomas analysed by the SI:
￿ 11 senescent
￿ 6 non-senescent
7 matched frozen/FFPE validation set adenomas:
(Enter % positive cells as values from 0 to 1)
Cryo FFPE
Adenoma
#13
#14
#18
#15
#16
#17
#19
SI
SI = 34.5 ￿ p-ERK + 13.9 ￿ HP1 + 11.4 ￿ PAI-1 – 19
SA--gal/Ki67
Non-senescent
Non-senescent
Non-senescent
Senescent
Non-senescent
Non-senescent
Non-senescent
Non-senescent
Senescent
Senescent
Senescent
Senescent
Senescent
Senescent
Proof of
Ras- and adenoma-
related senescence
Apply SI to CRC stage IV samples at diagnosis (n = 30),
test independence from clinical and molecular parameters,
and correlate with outcome to therapy (see Figure 1D)
Generating a
senescence surrogate
signature suitable
for FFPE samples
Probing the SI
as a predictor of
treatment outcome
Colorectal tissue samples
(normal, adenoma, carcinoma)
Human fibroblast cell line
(± Ras; as senescence reference)
as frozen samples
Exploit/confirm senescence by enzymatic SA--gal activity and
Ki67 immunostaining in situ (see Figure 1A–C)
Exploit/confirm senescence surrogate markers by
immunostaining in situ (see Figure 1C)
Adenoma learning set (n = 5) to generate a
senescence surrogate signature (SI; see Figure 2B)
Independent adenoma validation set (n = 17)
to confirm the SI (see Figure 2C)
As pelleted and FFPE section
Subset of most suitable markers
as FFPE material
as frozen and FFPE material
as FFPE material
Figure 2 Generation and validation of the senescence index (SI). (A) Technical flow diagram of the generation and application of the SI in a
Ras-transduced human fibroblast cell line and in colorectal tissue specimens. (B) Formula and cut-off values of the SI based on the expression p-ERK, HP1g
and PAI-1. Coefficients reflect the reciprocal average percentage of cells that stained positive for the respective marker in the learning adenomas to
normalise the relative weight of the three markers. The correction value –19 was chosen to set the discrimination threshold at 0, with the range between
 1 and þ1 considered ‘non-conclusive’. (C) The majority of validation set adenomas is senescent when analysed by the SI. A set of seven matched samples
(frozen and FFPE material from the same adenoma) underscores the high concordance between the SA-b-gal/Ki67- (see definition in Materials and Methods
section) and the SI-based assignment.
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UICC stage IV CRC samples before any drug treatment, and
assigned these cases, based on a cut-off value, to a (partly)
senescent vs a non-senescent group. All patients in this retro-
spective analysis received a 5-FU/LV-based first-line regimen.
Patients with senescent areas in their tumour biopsies experienced
a significantly longer PFS with a median PFS of 12.0 vs 6.0 months
when compared to the non-senescent group (Figure 1D). Notably,
both groups did not show statistically significant differences
regarding gender, age, pT and pN status as well as localisation of
the primary tumour (colon vs rectum), extent of distant metastasis
(one vs more than one site) or CEA serum levels at diagnosis, and
showed indistinguishable rates of proliferation (i.e. averaged
sample-wide Ki67 reactivity) and apoptosis (i.e. mean frequency
of cleaved caspase-3-positive cells) (data not shown). Interestingly,
K-Ras codon 12/13 mutations were found at a higher frequency
(P¼0.035) in the senescent group (Figure 1D, inset), suggesting
that Ras mutations, if associated with a senescent phenotype, may
not necessarily serve as a predictor of poor outcome, as reported
by several studies in the past (Benhattar et al, 1993; Andreyev et al,
1998, 2001; Roth et al, 2010).
DISCUSSION
This is the first report linking cellular senescence at diagnosis to
treatment outcome in cancer. Whether sporadic senescent cells
in manifest tumours represent a few remainders of the pre-
malignant condition, or indicate retained senescence susceptibility
throughout the tumour is currently not clear. Our study data
favour the latter explanation, postulating that TIS produced in
response to DNA-damaging chemotherapy in senescence-capable
tumour cells contributes to the overall outcome to therapy.
Notably, an inverse correlation between the expression level of
another senescence marker, macroH2A, and the risk of recurrence
has recently been reported for lung cancer patients (Zhang et al,
2005; Sporn et al, 2009). Additional studies are certainly needed to
clarify whether a greater extent of sporadic cancer cell senescence
indeed translates into a higher frequency of TIS-positive cells
in situ when analysed in re-biopsies a few days after chemo-
therapy. Moreover, a preserved pro-senescent cancer capability
might be therapeutically exploitable by novel senescence-inducing
strategies that do no longer damage DNA. The role of senescent
cells at diagnosis as a novel predictor of treatment outcome should
be further evaluated in larger prospective trials.
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